ABAMUNE Tablets 300 mg
Each film-coated tablet contains:
Abacavir sulfate …… 300 mg

ABAMUNE Tablets, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection.

Adults
The recommended oral dose of abacavir for adults is 600 mg daily administered as either 300 mg twice daily or 600 mg once daily in combination with other antiretroviral agents.

Dose a djustment in Hepatic Impairment: The recommended dose of ABAMUNE Tablets in patients with mild hepatic impairment (Child-Pugh score: 5 to 6) is 200 mg twice daily. To enable dose reduction, abacavir oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment and, therefore, ABAMUNE Tablets are contraindicated in these patients.

Abacavir sulfate has been associated with fatal hypersensitivity reactions. ABAMUNE Tablets SHOULD NOT BE RESTARTED FOLLOWING A HYPERSENSITIVITY REACTION TO ABACAVIR (see WARNINGS AND PRECAUTIONS, and UNDESIRABLE EFFECTS).

ABAMUNE Tablets are contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products (see WARNINGS AND PRECAUTIONS ).

ABAMUNE Tablets are contraindicated in patients with moderate or severe hepatic impairment.

ABAMUNE Tablets 300 mg Container of 30 tablets